Evaluation of osteopontin and CA125 in detection of epithelial ovarian carcinoma

European Journal of Gynaecological Oncology

Volumn 34, Issue 1, 2013, Pages 83-85

  Milivojevic, M ^a   Boskovic, V ^b   Atanackovic, J ^a   Milicevic, S ^a   Razic, S ^b   Kastratovic Kotlica, B ^b  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

CA125; Osteopontin; Ovarian cancer; Tumor markers

Indexed keywords

CA 125 ANTIGEN; OSTEOPONTIN;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVARY CYST; OVARY DISEASE; PELVIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; FEMALE; HUMANS; LINEAR MODELS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OSTEOPONTIN; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; ROC CURVE;

EID: 84875046117     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. National Institutes of Health Consensus Development Conference Statement: "Ovarian cancer: screening, treatment and follow-up". Gynecol. Oncol., 1994, 55, S4.
2. Holschneider C.H., Berek J.S.: "Ovarian cancer. Epidemiology, biology and prognostic factors". Semin. Surg. Oncol., 2000, 19, 3.
3. Anborgh P.H., Mutrie J.C., Tuck A.B., Chambers A.F.: "Pre-and post-translational regulation of osteopontin in cancer". J. Cell Commun. Signal., 2011, 5, 111.
4. Nakae M., Iwamoto I., Fujino T., Maehata Y.,Togami Sh., Yoshinaga M., Douchi T.: "Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen CA125 in predicting ovarian cancer". J. Obstet. Gynaecol. Res., 2006, 32, 309.
5. Tiniakos D.G., Yu H., Liapis H.: "Osteopontin expression in ovarian carcinomas and tumors of low malignant potential (LMP)". Hum. Pathol., 1998, 29, 1250.
6. Ye B., Gagnon A., Mok S.C: "Recent technical strategies to identify diagnostic biomarkers for ovarian cancer". Expert. Rev. Proteomics, 2007, 4, 121.
7. Langmar Z., Nemeth M., Vlesko G.,Kiraly M., Hornyak L., Bosze P.: "HE4-a novel promising serum marker in the diagnosis of ovarian carcinoma". Eur. J. Gynaecol. Oncol., 2011, 32, 605.
8. Hwang J., Na S., Lee H., Lee D.: "Correlation between preoperative serum levels of five biomarkers and relationships between these biomarkers and cancer stage in epithelial ovarian cancer". J. Gynecol. Oncol., 2009, 20, 169.
9. Kim K., Visinttin I., Alvero A. B., Mor G.: "Development and validation of a protein based signature for the detection of ovarian cancer". Clin. Lab. Med., 2009, 29, 47.
10. Moore R.G., Brown A.K., Miller M.C., Skates S., Allard W.J., Verch T. et al:. "The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass". Gynecol. Oncol., 2008, 108, 402.